National Vision EYE
$16.72 −$0.29 (-1.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.72 0.00%
Open$16.86
Prev close$17.01
Day range$16.59 – $17.62
Volume1.33M
Market cap$1.31B
P/E (TTM)20.4
Dividend yield–
EYE Stock News
Headlines matching National Vision or the EYE ticker, most recent first.
- Needs Well: Neezwell strengthens its IT infrastructure modernization services with an eye toward the AI era.
- China Merchants Securities International: Humanoid robots enter mass delivery phase; supply chain shifts toward platformization and modularity. Keep an eye on Ubtech Robotics (09880) and others.
- Aier Eye Hospital (300015): Back tax payments impact short-term profits; H-share listing preparations strengthen internationalization. Positive
- ANI Pharmaceuticals To Present Data From SYNCHRONICITY Phase 4 Clinical Trial Of Fluocinolone Acetonide Intravitreal Implant In Patients With Chronic Non-Infectious Uveitis Affecting The Posterior Segment Of The Eye In Oral Presentation During Uveitis...
- On September 30, Chaoju Eye Care (02219) repurchased 36,500 shares for HK$88,200.
- Shanghai Harbor (605598): Short-term profit margins under pressure; keep an eye on developments in the commercial space sector. Positive
- Needs Well: Promoting the development of data‑driven talent with an eye toward the AI era.
- Aier Eye Hospital: Legal Opinion of Hunan Qiyuan Law Firm Regarding the First Extraordinary Shareholders' Meeting of Aier Eye Hospital Group Co., Ltd. for 2026
- Xingqi Eye Medicine: Legal Opinion of King & Wood Mallesons Beijing on the Second Extraordinary Shareholders' Meeting of Shenyang Xingqi Eye Medicine Co., Ltd. for 2026
- Guggenheim Maintains National Vision(EYE.US) With Buy Rating, Cuts Target Price to $27 Negative
- Barclays Maintains National Vision(EYE.US) With Buy Rating, Maintains Target Price $27
- Cat Eye Entertainment (01896.HK): Film business under short-term pressure; summer box-office season showing signs of recovery; IP business expanding steadily.
- TopCloudAg (301556): Project timelines are weighing on near-term revenue; keep an eye on opportunities arising from business model evolution.
- Aier Eye Hospital (300015): Earnings in the first half of 2026 are expected to be volatile, with the refractive surgery business posting rapid growth. Positive
- Aier Eye Hospital (300015): Revenue in 26H1 grew steadily, with outpatient visits and surgical procedures continuing to rise. Positive
No comments yet — be the first to weigh in on EYE.
Sign in to join the discussion.